drugset / Trial / NCT05189015
Effect of Olmesartan on Angiotensin(1-7) Levels and Vascular Functions in Diabetes and Hypertension
RandomizedParallel-groupQuadruple-blindTreatment
Summary
In this study, we will assess the change of serum ACE-2, angiotensin(1-7), and vascular function after using olmesartan (an ARB), compared to conventional anti-hypertensive drug, amlodipine in hypertensive patients with T2DM.
Timeline
- Start
- 2021-01-01
- Primary completion
- 2022-06-30
- Completion
- 2023-06-30
Publications
- Natale P, Palmer SC, Navaneethan SD, Craig JC, Strippoli GF. Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2024 Apr 29;4(4):CD006257. doi: 10.1002/14651858.CD006257.pub2.
- Kim K, Moon JH, Ahn CH, Lim S. Effect of olmesartan and amlodipine on serum angiotensin-(1-7) levels and kidney and vascular function in patients with type 2 diabetes and hypertension. Diabetol Metab Syndr. 2023 Mar 11;15(1):43. doi: 10.1186/s13098-023-00987-1.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olmesartan | Other / unclassified | 20 mg | Oral |
| Subject | Olmesartan | Other / unclassified | 40 mg | Oral |